Tocilizumab in Systemic Lupus Erythematosus: Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study

Arthritis & Rheumatism
doi 10.1002/art.27221
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

SAT0231 Safety of Subcutaneous Belimumab in Patients With Systemic Lupus Erythematosus: A 6-Month Open-Label Extension Study

2017English

The Maraviroc Expanded Access Program — Safety and Efficacy Data From an Open-Label Study

HIV Clinical Trials
2015English

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Plasma Exchange in Systemic Lupus Erythematosus.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1981English

Type I Interferon and Systemic Lupus Erythematosus

Journal of Interferon and Cytokine Research
MedicineVirologyImmunologyCell Biology
2011English

A Study of the Efficacy of Immunosuppressants on Clinical Course of Systemic Lupus Erythematosus.

Japanese Journal of Clinical Immunology
1989English

A Study on Cardiovascular Manifestations of Systemic Lupus Erythematosus

Journal of Evolution of Medical and Dental Sciences
2017English

Efficacy and Safety of Two Ayurvedic Dosage Forms for Allergic Rhinitis: Study Protocol for an Open-Label Randomized Controlled Trial

Trials
MedicinePharmacology
2020English

Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells

Journal of Immunology
AllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy